Argenes Initiates Phase I Clinical Study of ARG098 (anti-Fas IgM monoclonal antibody), a Novel Therapeutics for Rheumatoid Arthritis, in Europe.: An article from: JCN Newswires

Argenes Initiates Phase I Clinical Study of ARG098 (anti-Fas IgM monoclonal antibody), a Novel Therapeutics for Rheumatoid Arthritis, in Europe.: An article from: JCN Newswires


This digital document is an article from JCN Newswires, published by Thomson Gale on October 5, 2007. The length of the article is 715 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after

Read more about allergy and ...